"It is my desire to continue building our world-class Small Molecule Drug Discovery organization to enable Genentech to help as many patients as possible."
I joined Genentech in May 2007 to lead the Small Molecule Discovery Chemistry Department after 25 years at the Pfizer Ann Arbor site, the last seven as Vice President of Chemistry. I was attracted to Genentech because of its rich culture of scientific excellence and dedication to innovative, ground-breaking research driven by the needs of patients.
What I have seen at Genentech during my tenure is a real commitment to discovering and developing potential therapies for difficult, life-threatening diseases where medical need is high and often patients are desperate for new medical advances. This commitment is a distinguishing feature that attracted me to Genentech.
J. Med. Chem. 1991, 34, 463-6.
As leader of Small Molecule Discovery Research, I oversee projects aimed at developing and delivering transformational medicines across a wide range of therapeutic areas, including cancer, immunology, neuroscience and infectious diseases. I am inspired by the patients who are waiting for the drugs that result from the outstanding work we do in the biotechnology and pharmaceutical industry. These patients are waiting, often desperately, for the hope brought by these potential drug therapies. Our efforts make a real difference in the lives of patients.